Solid Tumor Malignancy: Clinical Trials

1 trial for Solid Tumor Malignancy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Terminated 1

Follow Solid Tumor Malignancy: new trials by email Literature Review of Solid Tumor Malignancy trials Research Report on Solid Tumor Malignancy

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Pemigatinib - Solid Tumor Malignancy
Phase 2TerminatedIncyte Corporation1112019-10-172025-11-04

Narrower conditions

Acrocephalosyndactylia (1)

Broader conditions

Bone Diseases (1)  ·  Bone Diseases, Developmental (1)  ·  Congenital Abnormalities (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Craniofacial Abnormalities (1)  ·  Craniosynostoses (1)  ·  Dysostoses (1)  ·  Limb Deformities, Congenital (1)  ·  Musculoskeletal Abnormalities (1)  ·  Musculoskeletal Diseases (1)  ·  Syndactyly (1)  ·  Synostosis (1)

Interventions

pemigatinib (1)

Sponsors

Incyte Corporation (1)

Countries

Denmark (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Japan (1)  ·  South Korea (1)  ·  Spain (1)  ·  Switzerland (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Peter Langmuir, MD (1)

Results publications

PMID 38710951

NIH funding

2018 (1)